Project Grant HT94252311030

This $402,500 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support research at Duke University to evaluate the efficacy of targeting the CD40/CD154 signaling pathway as an approach to regulate the immune response and potentially induce tolerance in vascularized composite allograft (VCA) transplantation. The research aims to: 1) test the efficacy of anti-CD154 monoclonal antibody in naive and...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $210,867 to Drexel University for a 2-year period from February 2025 to January 2027. The project aims to develop a cell-based therapy using engineered "tolerogenic dendritic cells" that can be infused into donor kidneys prior to transplantation. This approach seeks to generate donor-specific immune tolerance...

This $598,894.00 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the development of a novel point-of-care rejection and immunosuppression monitoring assay (PRIMA) for vascularized composite allotransplantation (VCA). The primary recipient, Intelligent Optical Systems, Inc., is a manufacturer of optical sensing and instrumentation technologies that specializes in developing innovative medical...

This federal Project Grant award under the Cardiovascular Diseases Research program (CFDA 93.837) from the National Heart, Lung, and Blood Institute provides $185,579 to The University of Texas Southwestern Medical Center to conduct research on identifying novel pre-transplant biomarkers associated with the risk of rejection in heart transplant recipients. The key objectives are to validate proteomic biomarkers related to immune activation and rejection risk, perform RNA sequencing to analyze...

The University of Massachusetts Medical School will deliver the Active Rejection Micro-Patch Surveillance (ARMS) System for Vascularized Composite Allografts under a $280,000 cooperative agreement awarded by the Defense Health Agency on September 30, 2022. The three-year award will support the development of a monitoring system to detect early signs of rejection in vascularized tissue transplants through the Military Medical Research and Development program (CFDA 12.420). This program aims to...

This Project Grant award of $611,129, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop and validate a multi-organ-on-a-chip (MOC) platform to study the underlying mechanisms of antibody-mediated rejection (ABMR) in organ transplantation. The key products or services to be delivered through this funding include: Engineering a vascularized liver-on-a-chip (VLOC) and vascularized...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $642,056 to The Trustees of Columbia University in the City of New York to conduct research on the functional significance of plasma cell infiltrates in human cardiac allograft vasculopathy (CAV). The key objectives are to: 1) Characterize the graft-infiltrating plasma cells in human CAV using immunoglobulin gene...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $102,495 to investigate how a new combination immunotherapy approach affects the cardiac immune landscape and myocardial vulnerability. The principal investigator will leverage advanced technologies like spectral flow cytometry, single-cell sequencing, and computational biology to 1) analyze how cardiac T-cells respond to combined...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $1,310,631.89 to Yale University to develop and optimize antibody-targeted nanoparticles that can selectively deliver therapeutic siRNAs and mRNAs to the endothelial cells of solid organ allografts. The goal is to prevent the expression of surface proteins on graft endothelial cells that intensify host T...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $698,017 to the University of California, San Diego to develop a cardiovascular disease (CVD) vaccine. The key objectives are to: Develop a vaccine targeting the S100A9 protein, which regulates inflammation and is linked to atherosclerosis, in order to reduce S100A9 serum levels, inflammatory cytokines, and cholesterol to...